Senseonics Holdings, Inc. (SENS) Stock Price & How to Invest

Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.

Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.

5 analysts publish price targets on SENS, averaging $13.40 against a $5.03 price as of August 2026, or +166.4%. The published targets run from $8.00 to $18.00, a wide spread, and the ratings split 4 buy, 2 hold, 1 sell. Over the last six months there have been 0 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SENS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Senseonics Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Eversense 365 one-year differentiation. Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. The most optimistic published target, $18.00, assumes this works close to its best case.

The case against. Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. The most pessimistic target, $8.00, is roughly what SENS is worth if this bites instead.

Read the full bull and bear case on SENS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Senseonics Holdings, Inc.'s investor relations page or your broker.

• Full-year 2025 revenue: ~$35.3M (up from ~$22.5M in 2024)
• Q1 2026 revenue: ~$11.7M (up ~87% year over year)
• Full-year 2026 revenue guidance: ~$60M to $64M (raised; ~70-82% growth)
• Q1 2026 net loss: ~$32.3M (vs ~$14.3M a year earlier)
• Cash, equivalents and investments: ~$64.6M as of March 31, 2026 (debt ~$35.2M)
• Market capitalization: ~$280M (early June 2026)

These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales. Cash on hand and recent financing support the Eversense 365 launch and pipeline, but continued losses mean future capital raises are possible. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.

Other names that sit close to SENS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SENS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SENS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SENS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

If you believe a once-a-year implantable sensor is a durable point of differentiation in the crowded CGM market and that Senseonics can keep growing patient starts while improving margins after taking commercialization in-house, then SENS is a way to express that view. It remains a speculative small-cap: revenue is still modest, net losses are large, and the company faces two far bigger and better-funded competitors. Position sizing and risk tolerance matter more here than with an established profitable company, and the descriptive purpose of this page is to explain how to invest, not whether you should.

Whether SENS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SENS a buy or a sell?, and where the stock could go from here in the SENS stock forecast.

For income investors, whether SENS pays a dividend and how the payout looks is covered in does SENS pay a dividend? And to weigh SENS against a peer, read the full side-by-side comparisons: SENS vs DXCM and SENS vs ABT.